耐火贝塞特病中的巨型大动脉动脉瘤在托西利祖马布治疗下缩小:一个病例报告
Zi-Yi Song1, Xin Zhi2, Jia-Yi Geng3
1Department of Rheumatology and Immunology, Peking University People's Hospital, and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
ACR open rheumatology
|July 3, 2025
概括
互乐金-6 (IL-6) 受体对抗剂托西利祖马布在患有耐火贝切特病 (BD) 的患者中有效地管理了巨大的大动脉动脉瘤. 这种治疗导致了显著的动脉瘤收缩和持续控制BD活动.
科学领域:
- 类风湿病学 类风湿病学
- 血管医学 血管医学
- 免疫学 免疫学 免疫学
背景情况:
- 贝塞特病 (BD) 是一种慢性炎症性疾病.
- 血管并发症,包括巨大的大动脉动脉瘤,是BD的严重表现.
- 传统疗法往往无法管理具有血管参与的耐火性BD.
相关概念视频
Aneurysm III: Interprofessional Care
29
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
29
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Rheumatic Heart Disease III: Medical Management
36
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
36
Pericarditis III: Medical Management
28
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
28
Aortic Regurgitation III: Medical Management
51
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
51


